Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 65OTHER 63INDUSTRY 6NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Lymphoma 2Leukemia 2Recurrence 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Renal Cell 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3X-Rays 2Watchful Waiting 2Vinblastine 2Temozolomide 2Specimen Handling 2Radiotherapy 2Polymerase Chain Reaction 2Observation 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Melanoma × aldesleukin × Clear all
NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Eastern Cooperative Oncology Group

Phase 3 Completed
482 enrolled
Dermatologic

Melanoma

NCT00006237 2015-03-25

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

SWOG Cancer Research Network

Phase 3 Completed
432 enrolled 7 charts
Dermatologic

Melanoma

NCT00002669 2012-07-02

Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
90 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡